Fulcrum Therapeutics (FULC) EBT Margin (2020 - 2024)
Historic EBT Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 69.26%.
- Fulcrum Therapeutics' EBT Margin rose 27718700.0% to 69.26% in Q2 2024 from the same period last year, while for Dec 2024 it was 12.16%, marking a year-over-year increase of 34579000.0%. This contributed to the annual value of 12.16% for FY2024, which is 34579000.0% up from last year.
- Per Fulcrum Therapeutics' latest filing, its EBT Margin stood at 69.26% for Q2 2024, which was up 27718700.0% from 2842.25% recorded in Q4 2023.
- Fulcrum Therapeutics' EBT Margin's 5-year high stood at 69.26% during Q2 2024, with a 5-year trough of 8399.66% in Q1 2023.
- In the last 5 years, Fulcrum Therapeutics' EBT Margin had a median value of 1026.08% in 2020 and averaged 1885.27%.
- In the last 5 years, Fulcrum Therapeutics' EBT Margin plummeted by -73993500bps in 2023 and then soared by 27718700bps in 2024.
- Quarter analysis of 5 years shows Fulcrum Therapeutics' EBT Margin stood at 419.41% in 2020, then decreased by -11bps to 464.29% in 2021, then plummeted by -722bps to 3815.33% in 2022, then rose by 26bps to 2842.25% in 2023, then skyrocketed by 102bps to 69.26% in 2024.
- Its EBT Margin was 69.26% in Q2 2024, compared to 2842.25% in Q4 2023 and 3164.3% in Q3 2023.